long COVID

13 · 20 / page

Ask MedXY AI

Latest news

Tag

Infectious Diseasesfatiguefluvoxamine

Fluvoxamine Shows Promise for Treating Long COVID Fatigue: Results from Adaptive Randomized Trial

By MedXY|Apr 3, 2026

A randomized trial of 399 adults with long COVID fatigue found that fluvoxamine significantly reduced fatigue severity at 60 and 90 days compared to placebo, while metformin showed no benefit. The study represents a potential breakthrough i

Infectious Diseaseslong COVIDmetformin

long COVID

Latest news

Fluvoxamine Shows Promise for Treating Long COVID Fatigue: Results from Adaptive Randomized Trial

Metformin and Ursodeoxycholic Acid Fail to Improve Post-COVID Recovery: Insights from a Randomized Controlled Trial

Beyond the Virus: How Economic Instability and Social Context Drive Pediatric Long COVID Risk

Colchicine for Long COVID: Randomized Trial Finds No Benefit in Functional Recovery or Inflammatory Resolution

Long COVID-19 in Pregnancy: Elevated Risk Amidst Mild Omicron Infection in a Boosted Vaccinated Cohort During COVID-19 Endemicity

What, When and How to Measure Post COVID-19 Condition: The New Core Outcome Set for Clinical Trials

Remote Cognitive Training, Structured Rehabilitation and tDCS Failed to Improve Self‑Reported Cognitive Symptoms in Long COVID: Results from a 5‑Arm Phase 2 Randomized Trial

Persistent Olfactory Dysfunction Following SARS-CoV-2 Infection: Insights from the RECOVER Adult Cohort

Digital Biometric Measures in Long COVID: Insights from the STOP-PASC Randomized Clinical Trial Secondary Analysis

Unraveling Mitochondrial Dysfunction as a Key Pathological Feature in Long COVID Syndrome

COVID reinfection may raise risk of persistent symptoms by 35%

Long COVID and the Workforce: Navigating a Complex Path Back to Employment

Impact of Obesity on Long COVID: Insights from Primate Studies